Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-tazobactam and comparator susceptibilities were determined u...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2017-07, Vol.61 (7)
Main Authors: Shortridge, Dee, Castanheira, Mariana, Pfaller, Michael A, Flamm, Robert K
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
Anti-Infective Agents
Anti-Infective Agents - pharmacology
Cephalosporins
Cephalosporins - pharmacology
Drug Resistance, Multiple, Bacterial
Microbial Sensitivity Tests
Penicillanic Acid
Penicillanic Acid - analogs & derivatives
Penicillanic Acid - pharmacology
Pseudomonas aeruginosa - drug effects
Susceptibility
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible isolates, 87.6% were susceptible to ceftolozane-tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-tazobactam susceptible. activity against drug-resistant indicates ceftolozane-tazobactam may be an important agent in treating serious bacterial infections.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.00465-17